GAITHERSBURG, Md., February 15, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions EBS announced today that it has entered into an agreement to sell its travel health business to Bavarian Nordic (BVNRY) for a total consideration of up to $380 million, including potential future milestone payments. Under the terms of the Definitive Agreement, Bavarian Nordic will acquire the rights to VIVOTIF®, indicated for active immunization for the prevention of typhoid, and VAXCHORA®, indicated for active immunization for the prevention of cholera, as well as Chikungunya vaccine im Development stage candidate CHIKV VLP. Bavarian Nordic will also acquire Emergent’s manufacturing facility in Bern, Switzerland and development facilities in San Diego, California. Approximately 280 current Emergent employees are expected to transfer to Bavarian Nordic as part of the transaction.

“This agreement allows these important vaccines to continue to reach the patients and customers who need them and allows us to further sharpen our focus on protecting and improving life through our core products and contract manufacturing services,” said Robert G. Kramer , President of Emergent and CEO. “I would like to thank our Emergent teammates, who will be joining Bavarian Nordic, for their dedication in developing and delivering these products that address global health needs.”

The sale of its travel health business builds on Emergent’s previously announced strategic prioritization of its medical countermeasures products including ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), TEMBEXA® (Brincidofovir), RSDL® (Reactive Skin Decontamination Lotion Kit), several anthrax products and the opioid -Overdose reversal drug NARCAN® (naloxone HCl) nasal spray and contract development and manufacturing services companies. Together, these actions will improve profitability and position Emergent for steady, sustainable growth over the long term.

Emergent will discuss this transaction further during the conference call…